MYOK MyoKardia Inc.

57.16
+1.53  (+3%)
Previous Close 55.63
Open 55.86
Price To Book 4.51
Market Cap 2,636,334,041
Shares 46,117,975
Volume 66,329
Short Ratio
Av. Daily Volume 247,761

NewsSee all news

  1. MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients

    SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study

  2. MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019

    Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained,

  3. MyoKardia to Participate in September Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced its participation in the following upcoming investor conferences: Citi 14th Annual Biotech Conference in

  4. MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019

    SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC) Congress taking

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2Q 2020.
Mavacamten (MYK-461) - EXPLORER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 interim positive data released March 4, 2019. Data presented at ESC August 31, 2019 noted statistically significant changes in key biomarkers maintained.
Mavacamten (MYK-461) - PIONEER-OLE
Non-obstructive Hypertrophic cardiomyopathy (HCM)
Phase 2 top-line data due 4Q 2019.
Mavacamten (MYK-461) - MAVERICK-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2a top-line data due 4Q 2019.
MYK-491
Heart failure
Phase 1 commencement of dosing announced August 21, 2019 with top-line data due mid-2020.
MYK-224
Hypertrophic cardiomyopathy (HCM)

Latest News

  1. MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients

    SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study

  2. MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019

    Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained,

  3. MyoKardia to Participate in September Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced its participation in the following upcoming investor conferences: Citi 14th Annual Biotech Conference in

  4. MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019

    SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC) Congress taking